Fertility Preservation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Fertility preservation encompasses medical and surgical techniques that protect a person's ability to have biological children at a future date. The need arises in several contexts: cancer patients facing gonadotoxic chemotherapy or pelvic radiation; those undergoing surgery that may damage ovarian or testicular function; patients with conditions causing premature ovarian insufficiency (e.g., Turner syndrome, autoimmune diseases); and individuals or couples who wish to delay childbearing for personal, professional, or social reasons.

For women, the most established method is oocyte (egg) cryopreservation — stimulating the ovaries with gonadotrophins to produce multiple mature eggs, retrieving them transvaginally under sedation, and vitrifying (rapidly freezing) them for long-term storage. Embryo cryopreservation (freezing fertilised eggs) offers equivalent or marginally higher survival rates but requires a male partner or donor sperm at the time of freezing. For men, sperm cryopreservation is simple, non-invasive, and highly effective. Ovarian tissue cryopreservation — removing and freezing ovarian cortex strips for later reimplantation — is a newer technique particularly suited to prepubertal girls and women who cannot delay cancer treatment.

Fertility preservation decisions require timely consultation with a reproductive endocrinologist, ideally before starting cancer treatment. The process of egg freezing typically takes 2–3 weeks from start of ovarian stimulation to egg retrieval, which can usually be accommodated within the interval before chemotherapy begins. Multidisciplinary coordination between oncologists, reproductive specialists, and patient support teams is essential. Many comprehensive cancer centres now include oncofertility counselling as a standard component of care.

Oncofertility — preservation in the context of cancer — is the most common indication. Breast cancer, Hodgkin lymphoma, leukaemia, colorectal cancer, and gynaecological cancers are among the diagnoses most frequently leading to fertility preservation referral. Alkylating chemotherapy agents (cyclophosphamide, chlorambucil), platinum-based drugs, and pelvic or total body irradiation carry the highest gonadotoxic risk. Women with hormone receptor-positive breast cancer may use random-start stimulation protocols or natural cycle egg retrieval to minimise oestrogen exposure.

Non-oncological indications include elective egg freezing for age-related fertility decline (social egg freezing), premature ovarian insufficiency from autoimmune diseases or genetic conditions, endometriosis surgery that may reduce ovarian reserve, gender-affirming hormone therapy in transgender individuals before transition, planned haematopoietic stem cell transplantation, and pre-orchidectomy sperm banking for testicular cancer. Sperm banking for men before any gonadotoxic medical, surgical, or radiation treatment is a quick, low-cost intervention that should be offered routinely.

Women of reproductive age (typically up to 42–43 years for elective egg freezing, and any reproductive-age cancer patient) with adequate ovarian reserve (AMH above 0.5–1.0 ng/mL, antral follicle count above 5–7) are suitable candidates for egg freezing. Younger women and those with higher ovarian reserve will yield more eggs per cycle, improving long-term success probability. For oncology patients, candidacy is not necessarily limited by ovarian reserve — even one mature egg retrieved offers a future chance of pregnancy. Sperm banking for men is appropriate at any reproductive age before gonadotoxic treatment.

Women who are pregnant at the time of cancer diagnosis cannot undergo standard ovarian stimulation; ovarian tissue cryopreservation is an option for these patients and for prepubertal girls. Women with very poor ovarian reserve or active malignancy seeding the ovaries (e.g., some leukaemias) may not be suitable for ovarian tissue reimplantation due to the theoretical risk of reintroducing malignant cells. Genetic counselling is recommended for patients with hereditary cancer syndromes before undertaking fertility preservation.

Oocyte cryopreservation is the standard of care for postpubertal women without a male partner. Ovarian stimulation with gonadotrophins over 10–12 days, triggered with hCG or GnRH agonist, is followed by transvaginal ultrasound-guided egg retrieval under sedation. Mature eggs are vitrified and stored. Approximately 15–20 eggs are needed to achieve a reasonable live birth probability for women under 35; 25–30 for women aged 37–40. Multiple stimulation cycles may be needed to accumulate sufficient eggs.

Embryo cryopreservation follows the same stimulation and retrieval process but proceeds to fertilisation with partner or donor sperm and cryopreservation at the blastocyst stage. It provides the best per-unit survival and implantation rates but requires partner involvement at the time of freezing. Ovarian tissue cryopreservation does not require stimulation — ovarian cortical strips are removed laparoscopically and vitrified. Reimplantation after cancer remission has led to spontaneous pregnancies and IVF pregnancies; over 200 live births have been reported globally. Random-start ovarian stimulation protocols allow egg retrieval at any point in the menstrual cycle, minimising the delay before cancer treatment begins. Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

Egg freezing provides reproductive autonomy and insurance against future infertility from medical treatment or age. Vitrification has transformed egg survival rates — modern vitrified eggs survive thaw at rates of 80–90%, compared to 50–60% with older slow-freeze techniques. Cumulative live birth rates from frozen eggs depend on age at freezing: women who freeze eggs under 35 can expect a cumulative live birth rate of 40–60% from 15–20 eggs. Sperm cryopreservation preserves male fertility indefinitely — frozen sperm have been used successfully after over 20 years of storage.

For cancer survivors, fertility preservation provides hope of future parenthood that significantly reduces psychological distress during treatment. Studies show that patients who undergo fertility preservation experience lower anxiety and higher quality of life compared to those who do not, even in cases where preserved material is ultimately not used. Oncofertility counselling is therefore both a clinical and psychological intervention.

Ovarian stimulation for egg freezing carries the same risks as stimulation for IVF: mild OHSS occurs in up to 30% of stimulated cycles; severe OHSS is rare (less than 2%) and more common in women with PCOS. Egg retrieval carries a small risk of bleeding (less than 1%) and infection (less than 0.3%). Not all retrieved eggs will be mature, fertilise, or develop to transferable blastocysts. Cumulative success varies with age and egg number.

For ovarian tissue cryopreservation, laparoscopic surgery carries small risks of bleeding, infection, and anaesthetic complications. The theoretical risk of reintroducing malignant cells through tissue reimplantation is a genuine concern for leukaemia patients and requires careful case-by-case discussion. Social egg freezing should not be oversold as a reliable guarantee of future pregnancy — realistic counselling about the age-dependent success rates and the number of eggs required is essential to avoid false expectations.

After egg retrieval, patients resume normal activities within 24–48 hours. Mild bloating and pelvic discomfort are expected for a few days. For cancer patients, egg retrieval is timed to allow chemotherapy to begin within days to weeks of the procedure. Cryopreserved eggs, embryos, sperm, or ovarian tissue are stored in liquid nitrogen at -196°C; annual storage fees apply. Patients should update consent forms regarding storage duration and disposition of material.

When a patient is ready to use preserved material, thawed eggs are fertilised by ICSI, embryos are cultured to blastocyst stage and transferred in a programmed frozen embryo transfer cycle. Ovarian tissue reimplantation requires laparoscopic surgery; ovarian function typically returns within 3–6 months of reimplantation. Long-term follow-up of children born from fertility preservation has not identified any increased risk of congenital anomalies.

In the United States, a single egg freezing cycle costs USD 6,000–12,000 excluding medications (USD 3,000–6,000 additional); annual storage fees are USD 500–1,000 per year. UK private egg freezing costs GBP 3,500–6,000 per cycle. NHS funding for oncofertility is increasingly available but inconsistent. Charity funding is available from organisations such as Macmillan Cancer Support.

Medical tourism for fertility preservation is common, particularly for elective egg freezing. Spain, Czech Republic, and Greece offer egg freezing cycles for EUR 2,000–4,000 including medications. India offers competitive egg freezing packages at USD 1,500–3,500. Patients travelling abroad should ensure the clinic's embryology laboratory is certified for long-term gamete storage, that cryopreserved material can be transported internationally if needed, and that storage arrangements are contractually clear.

GnRH agonist co-treatment alongside chemotherapy (ovarian suppression) is sometimes used in women with hormone-insensitive cancers to temporarily suppress ovarian function and reduce gonadotoxic impact. Evidence for its effectiveness is improving, but ESHRE guidelines state it should not be used as the sole fertility preservation strategy. It is best used as an adjunct to egg or embryo freezing.

For women who lose ovarian function entirely after cancer treatment, donor egg IVF remains a highly effective pathway to pregnancy (live birth rates of 50–60% per transfer). For men who did not bank sperm before treatment, surgical sperm retrieval may recover sperm if spermatogenesis has recovered after treatment. Adoption and fostering are alternative paths to parenthood that should be acknowledged and supported throughout the fertility preservation counselling process.